Drug toxicity is a common cause of liver injury and
kidney failure. This study was designed to elucidate whether administration of high doses of
Ceftriaxone or
Vancomycin induce oxidative stress in liver as well as kidney, and to investigate the protective effects of
VRP 1020 with fixed dose combination of
ceftriaxone-
vancomycin (Immunox-V). Twenty four Mus musculus mice (weighing 30 +/- 5 g) were divided into four groups containing six mice in each group. The activities of
antioxidant enzymes such as
superoxide dismutase,
catalase and the level of malonaldialdehyde, as an marker of
lipid per oxidation, were measured to evaluate oxidative stress in homogenates of the liver and renal tissue.
Ceftriaxone or
vancomycin administration significantly increased malonaldialdehyde levels (p < 0.001) but significant decreased in
superoxide dismutase (p<0.01) and
catalase (p<0.001) activities. Co-administration of
VRP 1020 with FDC of Immunox-V
injections caused significantly decreased malonaldialdehyde levels (p< 0.001) and increased
superoxide dismutase (p<0.01) and
catalase (p<0.001) activities in liver and renal tissue when compared with other treated groups. Similarly, the levels of extracellular
antioxidant (
Creatinine and
Uric acid) were found to be significant lowered in Immunox-V treated group when compared to
ceftriaxone or
vancomycin alone treated group. These results indicate that chemical mediated technology of
VRP 1020 with fixed dose combination of Immunox-V can prevent
drug induced nephrotoxicity and oxidative stress which protects liver injury as well as renal tissue damage by reducing
reactive oxygen species which improve the activities of
free radical scavenging
enzymes.